Table 2.
Univariate and multivariate cox regression analysis of disease-free survival.
| Characteristics | Univariate cox analysis | Multivariate cox analysis | ||
|---|---|---|---|---|
| Hazard ratio (95%CI) | p value | Hazard ratio (95%CI) | p value | |
| Age (year) | ||||
| ≤50 | Reference | Reference | ||
| >50 | 1.723 (1.056–2.810) | 0.029* | 1.370 (0.810–2.310) | 0.243 |
| BMI | ||||
| ≤23 | Reference | |||
| >23 | 0.946 (0.581-1.540) | 0.823 | ||
| Menstrual status | ||||
| Premenopausal | Reference | |||
| Postmenopausal | 1.601 (0.974–2.632) | 0.064 | ||
| Histological grade a | ||||
| 1/2 | Reference | |||
| 3 | 0.988 (0.605–1.613) | 0.961 | ||
| Lymphovascular invasion | ||||
| No | Reference | Reference | ||
| Yes | 2.324 (1.358–3.979) | 0.002* | 1.560 (0.840–2.880) | 0.157 |
| Ki-67 index at diagnosis < 30% b | ||||
| No | Reference | |||
| Yes | 1.135 (0.655–1.964) | 0.652 | ||
| T stage c | ||||
| 1 | Reference | Reference | ||
| 2 | 0.863 (0.506–1.474) | 0.590 | 0.840 (0.490–1.460) | 0.543 |
| 3 | 1.021 (0.415–2.508) | 0.964 | 0.890 (0.350–2.250) | 0.802 |
| 4 | 3.886 (1.165–12.970) | 0.027* | 2.660 (0.770–9.270) | 0.123 |
| N stage c | ||||
| 0 | Reference | Reference | ||
| 1 | 2.452 (1.325–4.538) | 0.004* | 2.360 (1.250–4.430) | 0.008* |
| 2 | 2.898 (1.381–6.083) | 0.005* | 2.560 (1.190–5.500) | 0.016* |
| 3 | 5.788 (2.925–11.453) | <0.001* | 4.130 (1.910–8.920) | <0.001* |
| IronMLR score | ||||
| Low | Reference | Reference | ||
| High | 2.157 (1.171–3.974) | 0.014* | 2.310 (1.200–4.430) | 0.012* |
*p<0.05.
Histological grade at diagnosis was based on the degree of histological tumor differentiation.
The Ki-67, index at diagnosis indicates DNA, synthetic activity as measured using immunocytochemistry.
Diagnosed based on the AJCC, 2010 criteria (seventh edition).